

論文等 (2023 年 1 月-2023 年 12 月)

- **Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer**
Hashimoto T, Otsu S, Hironaka S, Takashima A, Mizusawa J, Kataoka T, Fukuda H, Tsukamoto S, Hamaguchi T, Kanemitsu Y.
Future Oncol 2023.7, 19(23):1593-1600 doi: 10.2217/fon-2023-0097 PMID: 37584156
- **C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel**
Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E
Sci Rep 2023.5, 13(1):8815 doi: 10.1038/s41598-023-34962-7 PMID: 37258608
- **Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321**
Kasai T, Mori K, Nakamura Y, Seki N, Ichikawa Y, Saito H, Kondo T, Nishikawa K, Otsu S, Bessho A, Tanaka H, Yamaguchi H, Kaburagi T, Imai H, Mori K, Ohtake J, Okamoto H
Cancer Med 2023.7, 12(14):14988-14999 doi: 10.1002/cam4.6135 PMID: 37226421
- **Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study**
Komori A, Otsu S, Shimokawa M, Otsuka T, Koga F, Ueda Y, Nakazawa J, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Shirakawa T, Mitsugi K
Int J Clin Oncol 2023.8, 28(8):1073-1081 doi: 10.1007/s10147-023-02354-6 PMID: 37209158
- **Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel**
Ide Y, Otsuka T, Shimokawa M, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Shinohara Y, Ueno S, Taguchi H, Honda T, Shibuki T, Nio K, Ureshino N, Mizuta T, Mitsugi K, Shirakawa T
Anticancer Res 2023.4, 43(4):1817-1826 doi: 10.21873/anticancer.16335 PMID: 36974805
- **Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer.**
Otsu S, Hironaka S.
Cancers (Basel) 2023.9, 15(18):4564. doi: 10.3390/cancers15184564. PMID: 37760533
- **Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer**
Fukahori M, Okabe Y, Shimokawa M, Otsuka T, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Makiyama A, Taguchi H, Honda T, Ushijima T, Miwa K, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Shirakawa T
Cancers (Basel) 2023.11, 13(1):19399 doi: 10.1038/s41598-023-46924-0 PMID: 37938630

- **Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study.**

Nakazawa J, Tsuruta N, Shimokawa M, Kawahira M, Arima S, Ido A, Koga F, Ueda Y, Komori A, Otsu S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Otsuka T, Shirakawa T, Mitsugi K.

Oncology 2023.10 doi: 10.1159/000527176 PMID: 36195058